HAMBURG, Germany – Paris-based company Curium has signed an exclusive agreement with U.S. firm Progenics Pharmaceuticals Inc. to develop and commercialize in Europe a small-molecule positron emission topography (PET) imaging agent designed by Progenics to visualize prostate cancer.
